Payment overview · 2025
General Payments
$37.54
2 reported records · 2 companies
Healthcare provider profile · identity verified
Michel Rodriguez Sanchez
Allopathic & Osteopathic Physicians|Internal Medicine · HIALEAH, FL · NPI 1841647690
Verified facts
What the public records show
CMS Open Payments records show Michel Rodriguez Sanchez received $37.54 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 60.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.72 | 60.5% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.82 | 39.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
76 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1150 | 324 |
| Losartan Potassium | Losartan Potassium | 838 | 207 |
| Gabapentin | Gabapentin | 705 | 151 |
| Omeprazole | Omeprazole | 671 | 206 |
| Lisinopril | Lisinopril | 660 | 169 |
| Metformin Hcl | Metformin Hcl | 475 | 128 |
| Sildenafil Citrate | Sildenafil Citrate | 463 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 108 |
| Xarelto | Rivaroxaban | 372 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 360 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 349 | 108 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 339 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 327 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 303 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 293 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 291 | 70 |
| Furosemide | Furosemide | 288 | 97 |
| Famotidine | Famotidine | 269 | 99 |
| Simvastatin | Simvastatin | 260 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 79 |
| Warfarin Sodium | Warfarin Sodium | 217 | suppressed |
| Folic Acid | Folic Acid | 204 | 69 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 197 | 65 |
| Trazodone Hcl | Trazodone Hcl | 187 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 53 |
| Carvedilol | Carvedilol | 174 | 52 |
| Mirtazapine | Mirtazapine | 168 | 54 |
| Glipizide | Glipizide | 151 | 50 |
| Atenolol | Atenolol | 147 | 33 |
| Glipizide Er | Glipizide | 139 | 39 |
| Benzonatate | Benzonatate | 133 | 76 |
| Donepezil Hcl | Donepezil Hcl | 129 | 37 |
| Hydrocortisone | Hydrocortisone | 126 | 48 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 125 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 123 | 53 |
| Nifedipine Er | Nifedipine | 118 | 34 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 115 | 29 |
| Finasteride | Finasteride | 109 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 109 | 63 |
| Eliquis | Apixaban | 107 | 22 |
| Mupirocin | Mupirocin | 104 | 61 |
| Alendronate Sodium | Alendronate Sodium | 101 | 40 |
| Metformin Hcl Er | Metformin Hcl | 92 | 31 |
| Baclofen | Baclofen | 91 | 40 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 91 | 21 |
| Montelukast Sodium | Montelukast Sodium | 89 | 24 |
| Lactulose | Lactulose | 86 | 40 |
| Buspirone Hcl | Buspirone Hcl | 85 | 40 |
| Meloxicam | Meloxicam | 84 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 36 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 76 | 48 |
| Dutasteride | Dutasteride | 73 | 29 |
| Lansoprazole | Lansoprazole | 71 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 28 |
| Allopurinol | Allopurinol | 61 | 25 |
| Celecoxib | Celecoxib | 61 | 40 |
| Silver Sulfadiazine | Silver Sulfadiazine | 61 | 20 |
| Memantine Hcl | Memantine Hcl | 60 | 20 |
| Ketoconazole | Ketoconazole | 58 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 17 |
| Ibuprofen | Ibuprofen | 56 | 31 |
| Clonidine Hcl | Clonidine Hcl | 55 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 14 |
| Loperamide | Loperamide Hcl | 53 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 52 | suppressed |
| Naproxen | Naproxen | 50 | 31 |
| Sertraline Hcl | Sertraline Hcl | 50 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 16 |
| Nystatin | Nystatin | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | 19 |
| Pregabalin | Pregabalin | 49 | 14 |
| Spironolactone | Spironolactone | 49 | 17 |
| Alprazolam | Alprazolam | 45 | 20 |
| Glimepiride | Glimepiride | 45 | 12 |
| Tramadol Hcl | Tramadol Hcl | 45 | 16 |
| Dapagliflozin | Dapagliflozin Propanediol | 43 | 13 |
| Ezetimibe | Ezetimibe | 43 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 14 |
| Temazepam | Temazepam | 41 | 14 |
| Bumetanide | Bumetanide | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 16 |
| Prednisone | Prednisone | 40 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 39 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 39 | suppressed |
| Alogliptin | Alogliptin Benzoate | 38 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 35 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 37 | 11 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Levoxyl | Levothyroxine Sodium | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Ciclopirox | Ciclopirox | 35 | suppressed |
| Clonazepam | Clonazepam | 35 | 11 |
| Digoxin | Digoxin | 34 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 34 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 34 | 14 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | 14 |
| Dapagliflozin-Metformin Er | Dapaglifloz Propaned/Metformin | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 23 |
| Sucralfate | Sucralfate | 27 | 13 |
| Propafenone Hcl | Propafenone Hcl | 26 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 25 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 18 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Estradiol | Estradiol | 24 | 11 |
| Chlorthalidone | Chlorthalidone | 23 | 12 |
| Colchicine | Colchicine | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 22 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.54 · 2 records | GlaxoSmithKline, LLC. | ImmunoCAP, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error